NIH Chief Varmus, In His Second Year, Credited With Reinvigorating Agency

Questions remain about the low-key director's handling of clinical research, Congress, and scientific misconduct Not yet two years into his tenure as head of the National Institutes of Health, Harold E. Varmus is getting high marks from many scientists for his low-key, but thorough efforts to rejuvenate the agency's biomedical research effort. Initiatives to sharpen the basic science being done on campus and to streamline the peer review of proposals from outside researchers are bringing new

Written byFranklin Hoke
| 13 min read

Register for free to listen to this article
Listen with Speechify
0:00
13:00
Share


Questions remain about the low-key director's handling of clinical research, Congress, and scientific misconduct
Not yet two years into his tenure as head of the National Institutes of Health, Harold E. Varmus is getting high marks from many scientists for his low-key, but thorough efforts to rejuvenate the agency's biomedical research effort. Initiatives to sharpen the basic science being done on campus and to streamline the peer review of proposals from outside researchers are bringing new energy to the health agency from top to bottom, they say.

"Varmus has looked at NIH afresh from, I think, every perspective, both intra- and extramurally," says Samuel C. Silverstein, chairman of the physiology and cellular biophysics department at Columbia University College of Physicians and Surgeons and president of the Federation of American Societies for Experimental Biology (FASEB).

Some scientists and others maintain that NIH director Harold E. Varmus has given short shrift to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies